Invivyd (NASDAQ:IVVD) Insider Timothy Edward Lee Sells 19,663 Shares

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 19,663 shares of Invivyd stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $1.54, for a total transaction of $30,281.02. Following the completion of the sale, the insider owned 138,681 shares of the company’s stock, valued at $213,568.74. This represents a 12.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Timothy Edward Lee also recently made the following trade(s):

• On Wednesday, February 18th, Timothy Edward Lee sold 20,964 shares of Invivyd stock. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12.

Invivyd Trading Up 6.5%

NASDAQ:IVVD opened at $1.65 on Thursday. The company has a market cap of $384.65 million, a PE ratio of -3.51 and a beta of 0.60. The company has a 50 day simple moving average of $2.19 and a two-hundred day simple moving average of $1.75. Invivyd, Inc. has a 12 month low of $0.46 and a 12 month high of $3.07.

Analysts Set New Price Targets

A number of research firms have issued reports on IVVD. BTIG Research restated a “buy” rating on shares of Invivyd in a research note on Wednesday, January 21st. D. Boral Capital reissued a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. HC Wainwright upped their target price on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of Invivyd

Several institutional investors have recently made changes to their positions in the business. Courier Capital LLC bought a new position in Invivyd in the 4th quarter worth approximately $25,000. Bronte Capital Management Pty Ltd. bought a new stake in shares of Invivyd during the fourth quarter valued at approximately $27,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Invivyd in the second quarter worth $27,000. DRW Securities LLC purchased a new position in shares of Invivyd in the fourth quarter worth $27,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after acquiring an additional 28,146 shares during the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Trending Headlines about Invivyd

Here are the key news stories impacting Invivyd this week:

• Negative Sentiment: Jill Andersen sold 34,939 shares on Feb. 18 at an average price of $1.58 (≈$55.2k); her holdings fell ~16.1% to 181,736 shares. SEC Filing
• Negative Sentiment: Jill Andersen sold 32,771 shares on Feb. 17 at $1.54 (≈$50.5k); that trade reduced her position by ~13.1%. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake declined ~15.1% to 117,717 shares. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his ownership fell ~12.4%. SEC Filing
• Negative Sentiment: William E. Duke (CFO) sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake dropped ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: William E. Duke sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his position fell ~13.3%. SEC Filing
• Negative Sentiment: Julie Green sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); her holdings declined ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: Julie Green sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); that trade lowered her stake ~13.3%. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 19,392 shares on Feb. 18 at $1.58 (≈$30.6k); his holdings fell ~14.5% to 114,487 shares. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 18,189 shares on Feb. 17 at $1.54 (≈$28.0k); his position declined ~12.0%. SEC Filing

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.